CJC-1295 DAC vs no DAC: what's the difference?

The short answer

DAC stands for Drug Affinity Complex. It is a chemical modification added to CJC-1295 that lets the peptide bind covalently to albumin in the bloodstream, which drastically slows its clearance. The DAC version keeps GHRH-receptor signalling elevated for days; the version sold as 'no DAC' produces a short pulse measured in minutes to hours.

The mechanism is the same in both cases — both are analogues of the first 29 amino acids of growth hormone releasing hormone acting on the same pituitary receptor. What differs is how long the signal persists, and that difference is a pharmacokinetic one, not a demonstrated difference in clinical benefit.

The terminology is also messier than it looks. 'CJC-1295 no DAC' is a market naming convention rather than a formal chemical designation, and products carrying that label are not guaranteed to be identical to one another.

What CJC-1295 is, briefly

CJC-1295 is a synthetic analogue of GHRH(1-29), the biologically active fragment of growth hormone releasing hormone. It binds the GHRH receptor on the anterior pituitary and prompts the release of endogenous growth hormone. Amino-acid substitutions make it resistant to the enzyme DPP-4, which otherwise degrades native GHRH within minutes.

That is the compressed version. Half-life, evidence grade, reported effects, side effects and the reasons it is usually paired with a ghrelin-receptor agonist are covered in full on the CJC-1295 peptide profile, linked below, and this guide does not repeat them.

What the DAC modification actually does

The Drug Affinity Complex is a maleimidoproprionic acid group attached to the peptide. Once injected, that group reacts with a free cysteine residue on serum albumin and forms a covalent bond. The peptide is then carried around as a passenger on a protein that the body deliberately keeps in circulation for weeks.

Two things follow. The bound peptide is largely hidden from the peptidases and from renal filtration that clear small free peptides in minutes, and the effective reservoir of drug in plasma is released only gradually. The result is a sustained, non-pulsatile elevation of GHRH signalling rather than a discrete pulse.

This is an established drug-design strategy rather than anything specific to peptides sold online — albumin binding is used deliberately across pharmacology to extend half-life. The mechanism is well characterised; what remains uncertain is what sustained rather than pulsatile GHRH stimulation does over months or years, which nobody has studied.

DAC vs no DAC, side by side

The practical distinctions, kept to what is actually established:

• DAC modification — with DAC: albumin-binding linker present. No DAC: absent; the peptide circulates free.
• Albumin binding — with DAC: covalent, forming a long-lived depot. No DAC: none.
• Pharmacokinetic profile — with DAC: sustained, continuous receptor stimulation. No DAC: a short pulse that decays quickly.
• Duration — with DAC: effects on GH and IGF-1 reported over several days from one dose. No DAC: minutes to a couple of hours.
• Signalling pattern — with DAC: continuous elevation, which departs from natural pulsatile GH release. No DAC: closer to a physiological pulse.
• Terminology — with DAC: the original CJC-1295 designation. No DAC: an informal market name, usually meaning modified GRF(1-29).
• Evidence and status — both: unapproved for general use; human data are limited and mostly pharmacokinetic rather than outcome-based.
• Main uncertainty — with DAC: the long-term consequences of continuous GHRH signalling. No DAC: what any given vial labelled that way actually contains.

Why the two get confused

The confusion is largely a naming accident. CJC-1295 was originally the name of the DAC-bearing compound; the shorter-acting analogue was properly called modified GRF(1-29) or CJC-1295 without DAC. Sellers began using 'CJC-1295' as an umbrella term and then appended 'DAC' or 'no DAC' to disambiguate, which inverted the original convention.

Four labels circulate for what are meant to be two molecules: CJC-1295 with DAC, CJC-1295 without DAC, modified GRF(1-29), and sometimes just 'CJC-1295' with no qualifier at all — which is genuinely ambiguous and could be either.

Because none of this naming is regulated, the label on a vial is a claim, not an analysis. Two products sold under the same name may differ in sequence, purity or content, so it is not safe to assume that everything marketed as 'no DAC' is chemically identical.

Does DAC make it more effective?

This is where marketing and evidence diverge most sharply. A longer exposure profile is easy to measure and easy to sell, and it is frequently presented as though it settles the question of which form works better. It does not.

Growth hormone is normally released in pulses, and the pulsatile pattern itself appears to carry biological information — receptor sensitivity and downstream tissue responses are not indifferent to whether a signal arrives in bursts or as a plateau. Sustained GHRH stimulation is therefore a different physiological state, not simply more of the same one.

What can be said is narrow: the DAC form raises IGF-1 for longer after a single injection. Whether that translates into better body composition, recovery or any other outcome, and at what cost in receptor sensitivity or safety, has not been established in controlled human trials for either form.

What the evidence actually shows

Sorting the claims by evidence type makes the gap obvious.

• Mechanistic and pharmacological — well supported. Albumin binding extends half-life; GHRH-receptor agonism raises GH. These are not in dispute.
• Human pharmacokinetic data — limited but real. Early-phase studies of the DAC compound measured dose-dependent, multi-day increases in GH and IGF-1 in healthy adults.
• Human clinical outcomes — largely absent. There are no adequately powered trials showing that either form improves body composition, recovery, sleep or any hard endpoint, and development of the DAC compound did not proceed to approval.
• Long-term safety — unknown for both. Sustained IGF-1 elevation is the specific open question, and it is why a history of cancer is a hard stop.
• Vendor and forum claims — not evidence. Anecdote and marketing copy describe expectations, not measured outcomes, and neither is a substitute for trial data.

Bottom line

The difference between CJC-1295 DAC and no DAC is the albumin-binding modification and, consequently, how long the compound stays active: days versus hours. The receptor target and the basic mechanism are the same.

The difference in duration is well established. The claim that it makes one form better is not — that is an inference from pharmacokinetics, and it is undercut by the fact that natural GH release is pulsatile. Both forms remain unapproved research compounds with thin human outcome data, and the naming used to sell them is unreliable enough that the label alone tells you little about what is in the vial.

Frequently asked questions

What does DAC mean in CJC-1295?

DAC stands for Drug Affinity Complex. It is a chemical modification — a maleimidoproprionic acid linker — attached to the peptide so that after injection it forms a covalent bond with circulating albumin. Albumin is a long-lived plasma protein, so binding to it shields the peptide from rapid enzymatic breakdown and renal clearance, and the compound persists in circulation far longer than the unmodified peptide.

Is CJC-1295 without DAC the same as modified GRF(1-29)?

In most commercial usage the two names refer to the same intended molecule: a 29-amino-acid GHRH fragment carrying stabilising amino-acid substitutions but no albumin-binding linker. Strictly, 'CJC-1295' was the name of the DAC-bearing compound, so 'CJC-1295 no DAC' is a market coinage rather than a formal designation. Because the naming is informal and unregulated, two products with the same label are not guaranteed to be the same substance or purity.

What is the main difference between CJC-1295 DAC and no DAC?

Albumin binding, and therefore duration of exposure. The DAC version produces a sustained elevation of GHRH signalling lasting days; the no-DAC version produces a short pulse that decays within a couple of hours. Both act on the same GHRH receptor with the same basic mechanism — the difference is how long that signal stays switched on, not what the signal is.

Does CJC-1295 DAC last longer?

Yes. Published pharmacokinetic work in humans on the DAC-bearing compound reported measurable plasma concentrations and raised growth hormone and IGF-1 for several days after a single dose, consistent with a multi-day terminal half-life. The unmodified GHRH fragment is cleared within minutes to a couple of hours. Exact figures vary between studies and product batches, so treat any single precise number quoted by a seller with caution.

Does DAC mean CJC-1295 is more effective?

Not automatically. Longer exposure is a pharmacokinetic property, not a demonstrated clinical outcome. Sustained GHRH signalling replaces the body's natural pulsatile pattern with a continuous elevation, and it is not established that continuous elevation produces better results — some physiology argues the opposite, since pulsatility appears to matter for how tissues respond. Neither form has approved clinical indications or long-term outcome data.